contract drug manufacturer, said it will acquire five US contract development and manufacturing organization sites from Merck KGaA for a “low- to mid-triple-digit million” Swiss-franc enterprise valuation, expanding its US footprint to nine sites from four. Management highlighted demand for bioconjugates and viral vectors, two fast-growing parts of modern medicine where customers want partners that can take a product from early development to full commercial supply.
Why should I care?
For markets: Lonza’s five-site US deal is a time-to-revenue bet that pays off after mid-2027.
In contract manufacturing, new capacity isn’t just concrete and stainless steel: it needs “tech transfer” (moving a customer’s process into the plant) and regulatory qualification so products can be sold. Buying ready-to-run sites can shorten that timeline, which is why Lonza is paying for existing facilities rather than building from scratch. Once a drug’s manufacturing process has been validated for launch, switching suppliers can be slow and risky, so revenue tends to be stickier than in many industrial businesses. If these sites help Lonza meet demand in bioconjugates and viral vectors, the market will likely focus less on any single day’s price move and more on whether the deal improves medium-term revenue visibility and the mix of higher-value commercial work.
